Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59155 | 0.98 | — | — | |
| SCHEMBL1857819 | 0.95 | LMNA (0.59) | LMNAKMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL3620504 | 0.95 | LMNA (0.59) | LMNAKMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10872417 | 0.95 | LMNA (0.59) | LMNAKMT2ACYP1A2CYP2D6CYP2C9 | |
| Ammonia Solution, Strong SCHEMBL4654664 | 0.95 | LMNA (0.59) | LMNAKMT2ACYP1A2CYP2D6CYP2C9 | |
| Water SCHEMBL1277045 | 0.95 | LMNA (0.59) | LMNAKMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2297517 | 0.95 | LMNA (0.59) | LMNAKMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10871994 | 0.95 | LMNA (0.59) | LMNAKMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL839318 | 0.95 | LMNA (0.59) | LMNAKMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL239942 | 0.95 | LMNA (0.59) | LMNAKMT2ACYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020142606-A1 | CATALYTIC SYSTEMS, METHODS, AND ARTICLES FOR DELIVERY OF OXYGEN TO SKIN | L'OREAL (FR) | 2020-07-09 | — | — | WO | claimed |
| US-20200214945-A1 | SKIN-BRIGHTENING COSMETIC MASK SYSTEM | L'OREAL (FR) | 2020-07-09 | — | — | US | claimed |
| US-10391047-B2 | Mouthrinse formulations comprising fluoride and a metal salt of pyrrolidone carboxylic acid | COLGATE-PALMOLIVE COMPANY (US) | 2019-08-27 | — | — | US | claimed |
| US-20170348216-A1 | Mouthrinse Formulations Comprising Fluoride and a Metal Salt of Pyrrolidone Carboxylic Acid | GABA INTERNATIONAL HOLDING GMBH (CH) | 2017-12-07 | — | — | US | claimed |
| EP-3223781-A1 | MOUTHRINSE FORMULATIONS COMPRISING FLUORIDE AND A METAL SALT OF PYRROLIDONE CARBOXYLIC ACID | GABA International Holding GmbH (CH) | 2017-10-04 | — | — | EP | claimed |
| WO-2016096028-A1 | MOUTHRINSE FORMULATIONS COMPRISING FLUORIDE AND A METAL SALT OF PYRROLIDONE CARBOXYLIC ACID | GABA INTERNATIONAL HOLDING AG (CH) | 2016-06-23 | — | — | WO | claimed |
| CN-118660903-A | Lipolytic peptides | 瓦尔德西布伦大学医院基金会研究所 | 2024-09-17 | — | — | CN | disclosed |
| US-11504312-B2 | Mouthrinse formulations | COLGATE-PALMOLIVE COMPANY (US) | 2022-11-22 | — | — | US | disclosed |
| EP-3233203-B1 | DYEING PROCESS STARTING FROM ORTHO-DIPHENOL | OREAL (FR) | 2021-11-24 | — | — | EP | disclosed |
| EP-3220886-B1 | COMPOSITION COMPRISING AN ORTHO-DIPHENOL DERIVATIVE, AN ALKALI METAL (BI)CARBONATE, A WATER-SOLUBLE ORGANIC SOLVENT AND A REDUCING AGENT | OREAL (FR) | 2021-04-28 | — | — | EP | disclosed |
| EP-3787592-A1 | COMBINATION OF EXTRACTS OF QUINQUINA AND OF LEONTOPODIUM ALPINUM AND OF THE MANGANESE SALT OF L-PYRROLIDONECARBOXYLIC ACID IN THE TREATMENT OF ALOPECIA | Pierre Fabre Dermo-Cosmétique (FR) | 2021-03-10 | — | — | EP | disclosed |
| CN-107249556-B | Mouthwash formulation comprising fluoride and metal salt of pyrrolidone carboxylic acid | 加巴国际股份有限公司 | 2020-09-01 | — | — | CN | disclosed |
| WO-2020142606-A1 | CATALYTIC SYSTEMS, METHODS, AND ARTICLES FOR DELIVERY OF OXYGEN TO SKIN | L'OREAL (FR) | 2020-07-09 | — | — | WO | disclosed |
| US-7857866-B2 | Dyeing method using a composition comprising an ortho-diphenol and comprising a wiping, drying or non rinsing stage | L'OREAL S.A. (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7833290-B2 | Composition comprising a derivative of hermatoxylin, of hematein, of brazilin or of brazilein, metal salt, hydrogen peroxide, and (bi)carbonate and hair dyeing method therewith | L'OREAL S. A. (FR) | 2010-11-16 | — | — | US | disclosed |
| US-20100154138-A1 | DYEING METHOD USING A COMPOSITION COMPRISING AN ORTHO-DIPHENOL AND COMPRISING A WIPING, DRYING OR NON RINSING STAGE | L'OREAL S.A. (FR) | 2010-06-24 | — | — | US | disclosed |
| US-20100154143-A1 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE ORTHO-DIPHENOL, METAL SALT, HYDROGEN PEROXIDE, (BI)CARBONATE AND SURFACE-ACTIVE AGENT, AND DYEING METHOD THEREWITH | L'OREAL S.A. (FR) | 2010-06-24 | — | — | US | disclosed |
| US-20100154144-A1 | COMPOSITION COMPRISING AT LEAST ONE ORTHO-DIPHENOL, ONE METAL SALT, HYDROGEN PEROXIDE, (BI)CARBONATE AND A BASIFYING AGENT AND HAIR DYEING METHOD THEREWITH | L'OREAL S.A. (FR) | 2010-06-24 | — | — | US | disclosed |
| US-20100150857-A1 | COMPOSITION COMPRISING AT LEAST ONE ORTHO-DIPHENOL, METAL SALT, HYDROGEN PEROXIDE AND (BI)CARBONATE AND HAIR DYEING METHOD THEREWITH | L'OREAL S.A. (FR) | 2010-06-17 | — | — | US | disclosed |
| US-20100146718-A1 | COMPOSITION COMPRISING A DERIVATIVE OF HERMATOXYLIN, OF HEMATEIN, OF BRAZILIN OR OF BRAZILEIN, METAL SALT, HYDROGEN PEROXIDE, AND (BI)CARBONATE AND HAIR DYEING METHOD THEREWITH | L'OREAL S.A. (FR) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100154144-A1 | COMPOSITION COMPRISING AT LEAST ONE ORTHO-DIPHENOL, ONE METAL SALT, HYDROGEN PEROXIDE, (BI)CARBONATE AND A BASIFYING AGENT AND HAIR DYEING METHOD THEREWITH | DSG1, KRT18, DSP | LMNA 2198/4885KMT2A 2046/4885CYP1A2 875/4885 |
| US-20100154138-A1 | DYEING METHOD USING A COMPOSITION COMPRISING AN ORTHO-DIPHENOL AND COMPRISING A WIPING, DRYING OR NON RINSING STAGE | DSG1, KRT18, DSP | LMNA 2756/4885KMT2A 1715/4885CYP1A2 2043/4885 |
| US-20100146718-A1 | COMPOSITION COMPRISING A DERIVATIVE OF HERMATOXYLIN, OF HEMATEIN, OF BRAZILIN OR OF BRAZILEIN, METAL SALT, HYDROGEN PEROXIDE, AND (BI)CARBONATE AND HAIR DYEING METHOD THEREWITH | KRT18, ALPG, BSG | LMNA 2282/4885KMT2A 2644/4885CYP1A2 3634/4885 |
| US-10391047-B2 | Mouthrinse formulations comprising fluoride and a metal salt of pyrrolidone carboxylic acid | PHPT1, NHERF1, PHF6 | LMNA 4744/4885KMT2A 1872/4885CYP1A2 1777/4885 |
| US-20170348216-A1 | Mouthrinse Formulations Comprising Fluoride and a Metal Salt of Pyrrolidone Carboxylic Acid | PHPT1, P4HA1, NHERF1 | LMNA 4733/4885KMT2A 2197/4885CYP1A2 2308/4885 |
| US-20100150857-A1 | COMPOSITION COMPRISING AT LEAST ONE ORTHO-DIPHENOL, METAL SALT, HYDROGEN PEROXIDE AND (BI)CARBONATE AND HAIR DYEING METHOD THEREWITH | DSG1, POLR1C, DSP | LMNA 2708/4885KMT2A 2881/4885CYP1A2 2202/4885 |
| US-20100154143-A1 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE ORTHO-DIPHENOL, METAL SALT, HYDROGEN PEROXIDE, (BI)CARBONATE AND SURFACE-ACTIVE AGENT, AND DYEING METHOD THEREWITH | DSG1, KRT18, DSP | LMNA 3488/4885KMT2A 2131/4885CYP1A2 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.